Sign In
Buy LLY
$1,116.11
-5.06 (-0.451%)
At Close: Aug 04, 2026
Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning Markets
12:42pm, Wednesday, 05'th Aug 2026
As of 11:50 AM ET, the Dow Jones Industrial Average (^DJI +0.83%) is up 0.80% to 54,521, and the S&P 500 (^GSPC +0.10%) has climbed 0.03% to 7,738, putting both in record-high territory. The Nasdaq Co
Inside Out: LLY and the Future of Weight Loss Drugs
12:00pm, Wednesday, 05'th Aug 2026
Matt Tuttle can't quite pronounce the name of Eli Lilly's (LLY) oral weight-loss drug, but that doesn't stop him from understanding its significance to the healthcare company's future. He reacts to th
Nasdaq Falls Over 100 Points; Eli Lilly Shares Gain On Upbeat Earnings
11:58am, Wednesday, 05'th Aug 2026
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling over 100 points on Wednesday.
ADP Cools to +44K, Earnings Show Beats from DIS, LLY & More
11:36am, Wednesday, 05'th Aug 2026
Today's ADP private-sector payrolls came in below the +75K forecast and less than half the downwardly revised +95K from June.
Lilly (LLY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:01am, Wednesday, 05'th Aug 2026
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates an
Eli Lilly shares rise on revenue beat, raised outlook
09:46am, Wednesday, 05'th Aug 2026
Eli Lilly and Co (NYSE:LLY) shares rose nearly 7% in early trading Wednesday after the drugmaker reported second quarter results that topped Wall Street revenue expectations and raised its full-year 2
Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates
09:16am, Wednesday, 05'th Aug 2026
Eli Lilly (LLY) came out with quarterly earnings of $8.38 per share, beating the Zacks Consensus Estimate of $6.01 per share. This compares to earnings of $6.31 per share a year ago.
Eli Lilly Stock Jumps on Earnings Beat Fueled by Weight-Loss Drugs
06:59am, Wednesday, 05'th Aug 2026
Eli Lilly hikes its full-year guidance after earnings handily beat analysts' forecasts.
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
06:45am, Wednesday, 05'th Aug 2026
Eli Lilly reported second-quarter earnings and revenue that easily beat estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
06:45am, Wednesday, 05'th Aug 2026
Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAA
BDF Gestion Has $21.63 Million Holdings in Eli Lilly and Company $LLY
03:57am, Wednesday, 05'th Aug 2026
BDF Gestion lowered its position in shares of Eli Lilly and Company (NYSE: LLY) by 3.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18
Eli Lilly Could Swing $65.9 Billion After Earnings
03:31pm, Tuesday, 04'th Aug 2026
Earnings are set to hit the tape in a tight window on Wednesday and the options market is already sketching out how much volatility traders are willing to pay for into the prints, according to Benzing
HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company's investigational FAK inhibitor narmafotinib in combination w
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
08:09am, Tuesday, 04'th Aug 2026
Eli Lilly and Company (NYSE:LLY) will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5.
Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?
07:30am, Tuesday, 04'th Aug 2026
Despite its relatively modest gains this year, Eli Lilly is still one of the most widely followed pharmaceutical stocks. Investors have already priced in strong growth for Mounjaro and Zepbound, makin
